Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy currently comes in two distinct pen formats in the UK: the original multi-dose pre-filled injection pen and the newer single-dose 7.2mg pen approved by the MHRA in April 2026. Both deliver semaglutide subcutaneously once a week, but they differ in design, dose range and who they suit. As a prescription-only medicine, Wegovy is dispensed only after a prescriber has assessed your suitability — your clinical history, not just your preference, determines which pen format is appropriate for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The standard Wegovy pen series covers the full escalation schedule: 0.25mg, 0.5mg, 1.0mg, 1.7mg and 2.4mg. Each pen comes pre-filled and is used once weekly; you work through the doses under prescriber guidance, typically spending around four weeks at each level. The pens are colour-coded by strength, which reduces the risk of picking up the wrong one from the fridge. They require needle attachment before each injection, and those needles should be changed for every use. If you want to keep a fresh supply of the correct fit, compatible replacement needles are available separately.
The titration approach exists because semaglutide's most common side effects (nausea, loose stools, indigestion) are dose-dependent and tend to ease once your body adjusts. Starting low and moving up slowly is how the prescriber manages tolerability, not a formality. The NHS semaglutide page covers what to expect at each stage of the schedule.
Maintenance at 2.4mg was the standard endpoint for most patients until the 7.2mg option arrived, and if you are currently at that level you can read about the Wegovy 1mg pen and how it fits into the escalation journey before moving on. Many people remain at 2.4mg long-term, and for a significant number it delivers meaningful, sustained weight loss. The Wegovy pen overview has more detail on the standard pen series, including storage guidance.
On 14 April 2026 the MHRA approved a dedicated single-dose 7.2mg Wegovy pen, announced via the GOV.UK news release. This is a different device: one pre-set weekly injection, an auto-dosing mechanism, a built-in covered needle that locks after use, and no separate needle to attach. For people who found the needle-attachment step fiddly (or who travel regularly and want a simpler routine) the design is a practical step forward.
There is a firm eligibility boundary, though. The 7.2mg pen is licensed only for adults with a BMI of 30 or above. It is not approved for the cardiovascular risk-reduction indication, and it is not a starting pen. Patients still begin the titration schedule at 0.25mg and work up through the standard doses; 7.2mg is the ceiling, reached only after tolerating 2.4mg. Clinical trials at this higher dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide at its highest licensed dose.
Whether you reach the 7.2mg level, and which pen design you use to get there, depends on the clinical picture your prescriber sees, and on stock availability at the time of review. Never assume a specific format will be ready to go; a prescriber will confirm what is appropriate at your consultation.
Both Wegovy pen types must be kept refrigerated between 2°C and 8°C before first use. After that, each has a limited period during which it can be stored at room temperature (the exact window is set out in the Patient Information Leaflet and the Wegovy SmPC on the eMC; always defer to those rather than any general summary. A good habit is to keep the pen in the fridge door, away from the freezer compartment, and to set a weekly reminder for the same day each week.
For disposal, used pens and attached needles are sharps. They should never go into a standard household bin. A 1-litre sharps container is the right receptacle; your local pharmacy or GP surgery can advise on collection points. This applies equally to the new 7.2mg single-dose format despite its self-locking needle, the whole pen counts as a sharp once used.
If you want a broader look at where Wegovy fits among available weight-loss treatment options, including how it compares with tirzepatide, that context is worth having before your consultation. And if you are curious whether the Ozempic pen you have seen discussed online is the same thing, it is not, Ozempic contains the same molecule but carries a diabetes licence, not a weight-management one.
A question our prescribers hear regularly is whether a patient can simply request the higher-dose pen because it sounds more effective. The honest answer is that dose and format follow clinical assessment, not patient preference alone. The prescriber looks at your current weight, any medical history, how you have responded to previous doses if you are transferring from another provider, and whether the 7.2mg pen is even the licensed option for your situation.
For people researching where to source Wegovy in the UK, the only legal route is a prescription from a regulated prescriber, dispensed by a pharmacy registered with the GPhC. At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber. If you order before midday on a working day and your prescription is approved, treatment is dispatched the same day and arrives free the next working day via DPD, in plain packaging. The pen volume and fill guide explains the physical specifications if you want to understand what you are receiving before it arrives.
Ready to find out which format is appropriate for you? Speak to our prescribers through a free consultation, no waiting list, same-day clinical review.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.